Briacell Therapeutics Corp (BCTX) Stock Price, Quote & News

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology

Sector: Healthcare

Phone: 604-921-1810

Fax: 604-921-1898

Website: briacell.com

Address:

Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

SmallCapVoice Dec. 2 at 12:39 PM

$BCTX to present three posters showing data suggesting some patients may live longer and new tests doctors could use to identify who benefits, furthering their potential success. https://feeds.issuerdirect.com/news-release.html?newsid=5527968702159550&symbol=BCTX

0 · Reply

MrTicker Dec. 2 at 12:33 PM

$BCTX BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025 GLOBENEWSWIRE 6:30 AM ET 12/2/2025 Three poster presentations at the San Antonio Breast Cancer Symposium (SABCS), now available and to be presented on December 10, 2025, highlight robust survival and clinical benefit data in Phase 2, plus positive key biomarker data from the pivotal Phase 3 The pivotal Phase 3 study of Bria-IMT+CPI in advanced metastatic breast cancer is ongoing with an interim analysis expected in 1H2026

0 · Reply

bmart44 Dec. 1 at 3:22 PM

$COCH $BCTX $TNMG $RDW : My Picks for the next 6 months

0 · Reply

Make_it_rain_2026 Nov. 30 at 10:26 PM

$BCTX https://nypost.com/2025/11/26/us-news/fda-chief-promises-powerful-new-treatments-for-cancer-neuro-disorders-under-trump-admin-in-pod-force-one-interview/

0 · Reply

JJBurch Nov. 28 at 1:51 PM

$BCTX $IXHL $QCLS Look at the gains on all three since my post And it’s JUST getting started Let’s get RICH(er) together gang

0 · Reply

BD12 Nov. 26 at 12:24 PM

$BCTX https://www.cp24.com/news/canada/2025/11/26/inside-a-canadian-biotech-firms-fight-to-prove-its-a-victim-of-stock-spoofing/

1 · Reply

Emerald_Stock_Alerts_ Nov. 25 at 9:18 PM

$BCTX BIG BUY ALERT NOW ✅ ALL IN GOING INTO DECEMBER ✅ DD DONE ☑️

0 · Reply

ZacksResearch Nov. 25 at 6:06 PM

$BCTX about to step into the spotlight at SABCS 🔥 BriaCell is rolling out positive biomarker and survival data across three clinical posters — including new insights from its Phase 2 study and differentiated biomarker findings from its pivotal Phase 3 program. These updates highlight how the company’s novel immunotherapies and off-the-shelf cell-based approaches could help deliver more precisely targeted treatment options for metastatic breast cancer. See the complete stock outlook here👉 https://www.zacks.com/stock/quote/BCTX?cid=sm-stocktwits-0-quote_overview-oc-22469&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_22469

0 · Reply

DunkenInvest Nov. 25 at 3:11 PM

$BCTX when we hit 150$ I'm happy. I'm never gonna be happy I guess 🤣 #letsgoBCTX

1 · Reply

JJBurch Nov. 25 at 2:52 PM

$OSRH congrats to all. The revaluation phase is barely started. Recent $10 price target given. Long long way to go $IXHL watch for major spike today. Manipulation is so laughably obvious. Watch move from .32 to above .35-.38 today prior to news. Big volume coming. $QCLS they are about to sell their bio assets for $20M cash. That will be a major mover. $BCTX price target of $150. Cancer cure way under the radar obviously. GLTA

0 · Reply

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Nov 25, 2025, 7:30 AM EST - 7 days ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Nov 20, 2025, 7:30 AM EST - 12 days ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Nov 18, 2025, 7:30 AM EST - 14 days ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Nov 7, 2025, 7:30 AM EST - 25 days ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Nov 4, 2025, 7:30 AM EST - 4 weeks ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Oct 22, 2025, 7:30 AM EDT - 5 weeks ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Oct 21, 2025, 7:50 AM EDT - 6 weeks ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:30 AM EDT - 6 weeks ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 20, 2025, 7:30 AM EDT - 6 weeks ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 7 weeks ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 3, 2025, 7:30 AM EDT - 2 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Aug 26, 2025, 7:30 AM EDT - 3 months ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 25, 2025, 7:30 AM EDT - 3 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 21, 2025, 12:00 PM EDT - 3 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 13, 2025, 7:30 AM EDT - 3 months ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Jul 31, 2025, 7:30 AM EDT - 4 months ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 30, 2025, 7:30 AM EDT - 4 months ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 29, 2025, 7:30 AM EDT - 4 months ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 25, 2025, 7:30 AM EDT - 4 months ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 16, 2025, 4:05 PM EDT - 4 months ago

BriaCell Therapeutics Announces Closing of $15 million Public Offering

Jul 15, 2025, 3:05 PM EDT - 5 months ago

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Jul 15, 2025, 7:30 AM EDT - 5 months ago

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

Jul 11, 2025, 7:30 AM EDT - 5 months ago

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

Jul 10, 2025, 7:30 AM EDT - 5 months ago

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

Jul 9, 2025, 7:30 AM EDT - 5 months ago

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

Jul 8, 2025, 7:30 AM EDT - 5 months ago

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

Jul 2, 2025, 7:30 AM EDT - 5 months ago

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

Jun 24, 2025, 7:30 AM EDT - 5 months ago

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

Jun 4, 2025, 7:30 AM EDT - 6 months ago

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

Jun 2, 2025, 7:30 AM EDT - 6 months ago

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

May 27, 2025, 7:30 AM EDT - 6 months ago

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

May 23, 2025, 7:30 AM EDT - 6 months ago

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

May 20, 2025, 7:30 AM EDT - 7 months ago

BriaCell CEO Letter to Shareholders

Apr 30, 2025, 7:30 AM EDT - 7 months ago

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

Apr 28, 2025, 4:05 PM EDT - 7 months ago

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

Apr 28, 2025, 7:30 AM EDT - 7 months ago

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

Apr 24, 2025, 8:00 PM EDT - 7 months ago

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

Apr 24, 2025, 10:11 AM EDT - 7 months ago

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher

Apr 24, 2025, 7:30 AM EDT - 7 months ago

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

Apr 23, 2025, 7:30 AM EDT - 7 months ago

BriaCell Announces Four Clinical Data Presentations at ASCO 2025

Apr 22, 2025, 7:30 AM EDT - 8 months ago

BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)

Apr 16, 2025, 7:30 AM EDT - 8 months ago

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

Mar 26, 2025, 8:00 AM EDT - 8 months ago

BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

Mar 20, 2025, 8:00 AM EDT - 9 months ago

Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast Cancer

Feb 5, 2025, 6:15 PM EST - 10 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Feb 5, 2025, 4:05 PM EST - 10 months ago

BriaCell Therapeutics Announces Closing of Public Offering

Feb 3, 2025, 7:59 PM EST - 10 months ago

BriaCell Therapeutics Announces Pricing of Public Offering

Feb 3, 2025, 4:45 PM EST - 10 months ago

BriaCell Therapeutics Announces Proposed Public Offering of Common Shares

Feb 3, 2025, 7:30 AM EST - 10 months ago

BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™

SmallCapVoice Dec. 2 at 12:39 PM

0 · Reply

MrTicker Dec. 2 at 12:33 PM

0 · Reply

bmart44 Dec. 1 at 3:22 PM

$COCH $BCTX $TNMG $RDW : My Picks for the next 6 months

0 · Reply

Make_it_rain_2026 Nov. 30 at 10:26 PM

$BCTX https://nypost.com/2025/11/26/us-news/fda-chief-promises-powerful-new-treatments-for-cancer-neuro-disorders-under-trump-admin-in-pod-force-one-interview/

0 · Reply

JJBurch Nov. 28 at 1:51 PM

$BCTX $IXHL $QCLS Look at the gains on all three since my post And it’s JUST getting started Let’s get RICH(er) together gang

0 · Reply

BD12 Nov. 26 at 12:24 PM

$BCTX https://www.cp24.com/news/canada/2025/11/26/inside-a-canadian-biotech-firms-fight-to-prove-its-a-victim-of-stock-spoofing/

1 · Reply

Emerald_Stock_Alerts_ Nov. 25 at 9:18 PM

$BCTX BIG BUY ALERT NOW ✅ ALL IN GOING INTO DECEMBER ✅ DD DONE ☑️

0 · Reply

ZacksResearch Nov. 25 at 6:06 PM

0 · Reply

DunkenInvest Nov. 25 at 3:11 PM

$BCTX when we hit 150$ I'm happy. I'm never gonna be happy I guess 🤣 #letsgoBCTX

1 · Reply

JJBurch Nov. 25 at 2:52 PM

0 · Reply

Ernesto62 Nov. 25 at 1:11 PM

$BCTX $IXHL $QCLS bullshit

0 · Reply

JJBurch Nov. 25 at 1:08 PM

$BCTX $IXHL $QCLS All three now in serious acceleration mode Congrats to all who followed! LFG!!!

0 · Reply

SmallCapVoice Nov. 25 at 12:49 PM

$BCTX is set to showcase major progress at SABCS 2025 with three posters highlighting positive Phase 2, strong biomarker data and momentum in its pivotal Phase 3 study. Fast Track status adds to the significance. Investors will want this on their radar. https://www.globenewswire.com/news-release/2025/11/25/3194231/0/en/BriaCell-to-Highlight-Positive-Phase-2-Phase-3-Clinical-Data-at-SABCS-2025.html

0 · Reply

Stock2Luv Nov. 25 at 3:30 AM

$BCTX https://www.msn.com/en-us/health/other/cancer-drug-made-20-000-times-more-potent-in-breakthrough/ar-AA1PNqfY?ocid=msedgdhp&pc=U531&cvid=69252220b47a4d89aaa882dfd28a7eb2&ei=11

0 · Reply

JJBurch Nov. 24 at 3:49 PM

$OSRH breakout confirmed Hold on and enjoy!! $IXHL absolutely the next to go. Hurry and load up $BCTX loading zone $QCLS Congrats to all. Making money together is the best. The very best.

1 · Reply

student56 Nov. 24 at 2:10 PM

$BCTX IN

0 · Reply

2maligators Nov. 24 at 1:01 PM

$BCTX 👀

0 · Reply

DunkenInvest Nov. 24 at 10:01 AM

$BCTX there's still time to save my Christmas 🤣 Come on now dawg 💸

0 · Reply

superguild Nov. 22 at 6:25 AM

$BCTX burch has only one gify. Guess he has a crush on leo

0 · Reply

JJBurch Nov. 21 at 7:34 PM

$BCTX $IXHL $QCLS Two out of three starting their moves is a great start!!!! Congrats all

1 · Reply

JediGreen Nov. 21 at 9:07 AM

$BCTX My past experiences with stocks with so little shares to go around and when the stampede of investors all of a sudden want to be apart of a stock with positive phase 3 results its crazy. I’ve tried to get in stokes before on phass 3s and I was never able to get orders filled and get in them because the shares are baught up so fast and definitely could see a huge gap up on positive phase 3 results. Have fun if you are short margin calls and not only losing your money but owing your broker money. 😆

1 · Reply

JediGreen Nov. 21 at 5:56 AM

$BCTX Say if there is an offering in December. probably be a favorable offering. Phase 3 read out in the first half a 2026 could happen any day starting 2026. Bullish BABY

0 · Reply

Market Cap	18.33M
Revenue (ttm)	0.00
Net Income (ttm)	-26.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	13,971
Avg Vol	71,832
Day's Range	N/A - N/A
Shares Out	1.88M
Stochastic %K	75%
Beta	1.21
Analysts	Hold
Price Target	$40.00